Pharmafile Logo
Pharmafocus logo
Advanced Search

regorafenib

Showing 7 posts of 7 posts found.

Bayer’s liver cancer drug meets primary endpoint in late stage trial

May 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Stivarga, late stage trial, liver cancer, phase III, regorafenib, trial

Bayer has announced positive results from a late-stage trial evaluating Stivarga (regorafenib) tablets for the treatment of patients with unresectable …

News
Bayer image

New drugs give Bayer record sales

February 26, 2015
Sales and Marketing Bayer, Eylea, Radium-223 chloride, Stivarga, Xarelto, adempas, aflibercept, dekkers, german, regorafenib, riociguat, xofigo

Bayer has reported strong financial results for 2014 driven primary by sales of new medicines, although controversy surrounding its anti-clotting …

News
Bayer image

Bayer cancer drug meets Phase III goal

April 3, 2012
Research and Development, Sales and Marketing Bayer, Cancer, Glivec, Novartis, phase III, regorafenib

Bayer’s stomach cancer pill regorafenib has significantly improved progression free survival in late-stage patients. Results from the Phase III trial …

News
Bayer image

Bayer’s colorectal cancer drug increases survival

January 19, 2012
Research and Development, Sales and Marketing Bayer, colectoral cancer, regorafenib

Bayer and Onyx’s colorectal cancer drug regorafenib increased overall survival for late-stage patients, according to new data. The Phase III …

News
Bayer

FDA fast-tracks Bayer’s GIST drug regorafenib

May 10, 2011
Sales and Marketing Bayer, GIST, regorafenib

The assessment of Bayer HealthCare’s investigational drug regorafenib is to be fast-tracked by US authorities for the treatment of stomach …

News

Bayer’s regorafenib gains orphan status for GIST

February 4, 2011
Research and Development, Sales and Marketing Bayer, FDA, GIST, gastrointestinal stromal tumours, orphan drug, regorafenib

Bayer’s investigational compound regorafenib has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumours (GIST) …

News

Bayer colon cancer drug moves into phase III

May 11, 2010
Research and Development Bayer, colorectal cancer, regorafenib

Bayer Schering Pharma will shortly begin phase III tests of its investigational compound regorafenib for patients with metastatic colorectal cancer.  …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025